LA
ALXN

Leonetti & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Leonetti & Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-40,475
Closed -$6.32M – 40
2014
Q2 		$6.32M Sell
40,475
-175
-0.4% -$27.6K 2.17% 14
2014
Q1 		$6.18M Buy
40,650
+450
+1% +$71.6K 2.08% 15
2013
Q4 		$5.34M Buy
+40,200
New +$4.82M 1.85% 16

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Leonetti & Associates's ALXN Position: Q3 2014 in Review

Leonetti & Associates sold out of Alexion Pharmaceuticals (ALXN) in Q3 2014, closing a stake of 40,475 shares — an estimated $6.32M sold.

Leonetti & Associates first reported a position in ALXN in Q4 2013 and held it in 3 quarters. The position peaked at $6.32M in Q2 2014. 522 funds tracked by Wall St. Rank hold ALXN as of Q3 2014.

  • Leonetti & Associates reported no remaining Alexion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Leonetti & Associates sold 40,475 Alexion Pharmaceuticals shares in Q3 2014, an estimated $6.32M.
  • Leonetti & Associates first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Leonetti & Associates's Alexion Pharmaceuticals position peaked at $6.32M in Q2 2014.
  • 522 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2014.

Based on Leonetti & Associates's 13F filing for Q3 2014, filed 14 Nov 2014.